Sign In
Buy ABSI
$10.21
-0.390 (-3.68%)
At Close: Jul 13, 2026
Absci Reports Second Quarter 2021 Financial and Operating Results
08:30am, Tuesday, 07'th Sep 2021
VANCOUVER, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic po
Shares of protein discovery platform Absci pop in market debut
02:27pm, Thursday, 22'nd Jul 2021
Absci Corp., a Vancouver company behind a multi-faceted drug development platform, went public on Thursday. It's another sign of snowballing interest in new approaches to drug development – a tradit
Couchbase and 5 Other Companies Are Going Public. What You Need to Know.
01:05pm, Thursday, 22'nd Jul 2021
Couchbase, Ryan Specialty Group, and four other companies are scheduled to list their shares Thursday as the surge of IPOs continues.
IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)
12:15pm, Thursday, 22'nd Jul 2021
Absci, a synthetic biology company whose platform technology aids in the drug discovery process, is going public today.
Absci Announces Pricing of Initial Public Offering
07:03pm, Wednesday, 21'st Jul 2021
VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced
AbSci Proposes Terms For $200 Million IPO
01:12pm, Tuesday, 20'th Jul 2021
AbSci Proposes Terms For $200 Million IPO
